Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPD476 extension study for maintenance of ulcerative colitis remission
2004-000734-36Phase 3Completed
- Sponsor
- Takeda
- Start
- Oct 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of Salcrozine in autoimmune colitis (2 arms), sponsored by Takeda. Primary endpoint: Primary safety and tolerability endpoint. Started Oct 2004; status: completed.
02
Drugs
Salcrozine
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2004-000734-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000734-36.